Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Trial participants receiving the highest dose of CK-2017357 showed symptom improvement in the first stage of an ongoing phase 2 trial of this experimental drug
Posted on Tuesday, December 13, 2011 - 12:15, By: Amy Madsen
In the first stage of an ongoing phase 2 clinical trial to test the experimental therapy CK-2017357 in amyotrophic lateral sclerosis (ALS), the drug was found to be safe and well-tolerated.
Participants who received the highest dose showed improved scores on tests that measure motor and breathing...